Technologies

Pharmaceuticals & Vitamin D : Inflammation

Pharmaceuticals & Vitamin D Portfolios

Technologies

New Compounds for Treating High Blood Cholesterol and More

UW–Madison researchers have now developed a method using a rhodium-containing catalyst to make indole compounds, specifically cyclopropyl indoles and cyclohepta[b] indoles. The compounds may be developed into new pharmaceuticals to treat a variety of conditions.
P150140US02

SIgA Protein as Heath Supplement for Animals, Humans

UW–Madison researchers have developed a method for producing large quantities of animal- and human-grade sIgA. The protein is isolated from the intestinal fluid/lining of swine or cows, enriched and purified. The process is similar to how heparin, the common anticoagulant, is produced.
P120329US01

Preventing Septic Shock and Death with Peptide Antibodies

UW–Madison researchers have identified gastrointestinal tract, e.g., mucosal, inflammation as a key factor in SIRS. From this breakthrough, they have developed oral peptide antibodies to control the inflammation and/or prevent translocation of intestinal luminal bacteria into systemic circulation. The antibodies specifically bind sPLA2-IB, a pancreatic enzyme traditionally thought to only be involved in the digestion of dietary phospholipids. The antibodies are prepared using standard techniques and may be humanized or avian egg yolk antibodies. They are preferably administered as an oral pharmaceutical.
P120312US01

Method to Increase Feed Efficiency by Reducing Endotoxin-Induced GI Tract Inflammation

UW-Madison researchers have developed a method for improving feed efficiency in animals by reducing the binding between bacterial endotoxin and its receptors in the animal’s gastrointestinal tract. The method involves administering an agent that can reduce the formation of the signal transduction complex of endotoxin, TLR4, and CD14 on cells within the gastrointestinal tract. Preferably, the agent is an antibody against the extracellular domain of TLR4 or CD14. Reducing the binding between endotoxin and its receptors reduces gastrointestinal inflammation, leading to improved gut health, enhanced growth and increased feed efficiency.
P03399US

Using Conjugated Linoleic Acid to Inhibit Cyclooxygenase-2 and Reduce Inflammation

UW-Madison researchers have developed a COX inhibitor that does not cause the ulceration associated with COX-1 inhibition or cardiovascular problems associated with COX-2 inhibition. Conjugated linoleic acid (CLA) relieves pain and inflammation by inhibiting COX-2 without negatively affecting the digestive tract or cardiovascular system. Until now, CLA has not been recognized as a COX-2 inhibitor.
P99048US